The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel-Reference-Cited by-同舟云学术

The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel

Published:2005-06 Issue:6 Volume:34 Page:819-836
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Hochberg Marc C.,Lebwohl Mark G.,Plevy Scott E.,Hobbs Kathryn F.,Yocum David E.

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference116 articles.

1. Immunex Corp. Enbrel [package insert]. Seattle, WA, 2002.

2. Centocor Inc. Remicade [package insert]. Malvern, PA, 2003.

3. Abbott Laboratories. Humira [package insert]. North Chicago, IL, 2003.

4. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy;Kavanaugh;J Rheumatol,2000

5. The TNF receptor superfamily of cellular and viral proteins;Smith;Cell,1994

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease;Wiener klinische Wochenschrift;2024-05-24

2. Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy;African Health Sciences;2023-07-13

3. Production of recombinant human tumor necrosis factor receptor- IgG1 Fc domain fusion protein expressed by genetically CHO- DG44 cells;Journal of Cellular Biotechnology;2022-09-20

4. The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up;British Journal of Dermatology;2021-06-08

5. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy;Cancers;2021-02-02